BeyondSpring Inc

Most Recent

  • BeyondSpring information center
    Healthcare

    BeyondSpring (BYSI) Stock Is a Good Investment, Wait for Better Price

    By Ambrish Shah
  • uploads///Spectrum Pharmaceuticals Pipeline
    Company & Industry Overviews

    An Overview of Spectrum Pharmaceuticals’ Drug Pipeline

    Spectrum Pharmaceuticals (SPPI) obtained exclusive rights to commercialize Poziotinib from Hanmi Pharmaceutical (HANPF) under an in-license agreement in 2015.

    By Kenneth Smith
  • uploads///VKTX ana reco
    Company & Industry Overviews

    What Viking Therapeutics’ Valuation Trend Indicates

    In October, of the seven analysts covering Viking Therapeutics, one has given its stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///Spectrum Pharmaceuticals Revenue Trend
    Company & Industry Overviews

    Chart in Focus: Spectrum Pharmaceuticals’ Financials

    In 3Q17, Spectrum Pharmaceuticals (SPPI) raised $114.0 million from the sale of 12.6 million shares through its security offering program.

    By Kenneth Smith
  • uploads///Analysts Ratings for Spectrum Pharmaceuticals
    Company & Industry Overviews

    Analysts’ Recommendations for Spectrum Pharmaceuticals

    Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.